Clofibrate and nafenopin (SU-13437): effects on plasma clearance and tissue distribution of chylomicron triglyceride in the dog.
D000273:Adipose Tissue / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D000818:Animals; D002247:Carbon Isotopes; D002914:Chylomicrons / Q000097:blood / Q000378:metabolism*; D002994:Clofibrate / Q000494:pharmacology*; D004285:Dogs; D005215:Fasting; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008071:Lipoprotein Lipase / Q000037:antagonists & inhibitors / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009132:Muscles / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D009255:Nafenopin / Q000494:pharmacology; D010169:Palmitic Acids / Q000378:metabolism; D011422:Propionates / Q000494:pharmacology*; D012965:Sodium Chloride; D014280:Triglycerides / Q000097:blood / Q000378:metabolism*
D002247:Carbon Isotopes; D002914:Chylomicrons; D000960:Hypolipidemic Agents; D010169:Palmitic Acids; D011422:Propionates; D014280:Triglycerides; D009255:Nafenopin; D012965:Sodium Chloride; D008071:Lipoprotein Lipase; D002994:Clofibrate